Pharming Group N.V. announced a public cash offer to acquire all shares of Abliva AB, a move designed to strengthen Pharming’s late-stage pipeline. The proposed acquisition values Abliva at approximately US$66.1 million.
Abliva’s lead product, KL1333, is currently in a pivotal clinical trial for mitochondrial DNA-driven primary mitochondrial diseases and has already achieved a positive interim analysis. This asset is expected to enhance Pharming's portfolio with a potential first-in-disease therapy.
Pharming stated that no external funding will be required to finance the acquisition or the subsequent development costs for KL1333. This indicates a strong financial position and a strategic use of existing capital for pipeline expansion.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.